Table 2.
Clinical features of subjects on palivizumab with HRSV infections or other viral infections
| HRSV |
Other viral infectionsa |
No virus detected |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| All visits | Outpatient consultations | Hospitalizations | All visits | Outpatient consultations | Hospitalizations | All visits | Outpatient consultations | Hospitalizations | |
| (n = 11) | (n = 10) | (n = 1) | (n = 22) | (n = 19) | (n = 3) | (n = 57) | (n = 47) | (n = 10) | |
| Mean age at the time of NPA (months) | 7.4 | 7.8 | 3.6 | 7.6 | 7.7 | 6.5 | 9.2 | 7.8 | 15.6 |
| Mean interval between symptoms onset and NPA (days) | 5.5 | 5.1 | 9 | 3.9 | 3.7 | 5.3 | 5.9 | 5.8 | 6.3 |
| Feverb (%) | 9.1 | 10 | 0 | 59.1 | 57.9 | 66.7 | 31.6 | 25.5 | 60 |
| Cough (%) | 100 | 100 | 100 | 90.9 | 89.5 | 100 | 77.2 | 80.8 | 60 |
| Wheezing (%) | 45.5 | 50 | 0 | 22.7 | 21.1 | 33.3 | 31.6 | 36.2 | 10 |
| URTIb (%) | 36.4 | 40 | 0 | 77.3 | 78.9 | 66.7 | 78.9 | 85.1 | 50 |
| Bronchiolitis (%) | 72.7 | 70 | 100 | 36.4 | 36.8 | 33.3 | 35.1 | 38.3 | 20 |
| Pneumonitis (%) | 0 | 0 | 0 | 4.6 | 0 | 33.3 | 3.5 | 2.1 | 10 |
| Croupb (%) | 9.1 | 10 | 0 | 9.1 | 10.5 | 0 | 0 | 0 | 0 |
| Otitis media (%) | 9.1 | 10 | 0 | 0 | 0 | 0 | 8.8 | 6.4 | 20 |
| Pharyngitis (%) | 9.1 | 10 | 0 | 0 | 0 | 0 | 5.3 | 6.4 | 0 |
| Flu-like illnessb (%) | 0 | 0 | 0 | 13.6 | 15.8 | 0 | 0 | 0 | 0 |
Note: URTI: upper respiratory tract infection; NPA: nasopharyngeal aspirate; HRSV: human respiratory syncytial virus.
a
Infections with influenza A or B, parainfluenza viruses, human metapneumovirus and adenoviruses.
b
p < 0.05 by comparing the three study groups.